Aldeyra Therapeutics (ALDX) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 23.5% versus a loss of 83.1%. Xilio Therapeutics is the larger company by market cap ($59.3 million vs $57.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | XLO |
|---|---|---|
| Share price | $0.9477 | $9.01 |
| Market cap | $57.17M | $59.29M |
| 1-day change | -1.14% | 0.00% |
| YTD return | -81.70% | +0.56% |
| 1-year return | -83.14% | -23.48% |
| 5-year return | -88.64% | — |
| EPS (TTM) | $-0.38 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $12.59 |
| 52-week low | $0.862 | $6.47 |
| Distance from 52-week high | -84.02% | -28.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +596.42% | +121.98% |
| Average volume | 1.18M | 19.07K |
| Shares outstanding | 60.33M | 6.58M |
| Employees | 6 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed ALDX by 59.7 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Healthcare · Biotechnology · 6 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Healthcare · Biotechnology · 76 employees
ALDX vs XLO FAQ
Which is bigger, Aldeyra Therapeutics or Xilio Therapeutics?
Xilio Therapeutics (XLO) is larger, with a market capitalization of $59.29M compared with $57.17M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or XLO?
XLO returned -23.48% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.